Parkinson's Disease Evaluated by PET and the Effect of Memantine

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose of study: To investigate whether the NMDA antagonist Memantine has a substantial effect of brain metabolism in patients with Parkinson's disease (PD), using Positron Emission Tomography (PET).

Background: Disturbances in brain metabolism is thought to contribute to degeneration of neurons in brain of PD patients. Production of toxic oxygen radicals and presence of too much excitatory neurotransmitter (glutamate) due to over activity is involved. These factors can theoretically be alleviated by memantine.

Hypothesis: Memantine decreases metabolism in areas in PD brain known to be over-active. Decreases in cerebral blood flow and oxygen metabolism in these areas will be the consequence and this can be detected by PET.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborator: Lundbeck Foundation
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Parkinson's Disease (British Brain Bank Criteria)

• Age 50-70y

Exclusion Criteria:

• Tobacco use

• Any serious medical conditions (Heart disease, kidney disease, liver disease, endocrinological disorders etc)

• Metal implants contraindicating MR scan

• Drug use affecting the central nervous system

• Psychiatric disorders

• Head trauma or any disorders of the head, skull or brain

• Drug addiction or use of any kind of illegal substance affecting the central nervous system

• Pregnancy